Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

InflaRx N.V. - Common Stock (NQ:IFRX)

1.700 -0.050 (-2.86%)
Streaming Delayed Price Updated: 3:51 PM EDT, Sep 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about InflaRx N.V. - Common Stock

< Previous 1 2 3 4 5 Next >
Top movers analysis one hour before the close of the markets on 2025-08-29: top gainers and losers in today's session.
Curious to know what's happening on the US markets one hour before the close of the markets on Friday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Top movers in Friday's session
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements. 
Via Chartmill
Earnings Scheduled For August 7, 2025
 
Via Benzinga
Earnings Scheduled For May 7, 2025
 
Via Benzinga
Preview: InflaRx's Earnings
 
Via Benzinga
Earnings Preview: InflaRx
 
Via Benzinga
Earnings Preview: InflaRx
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
Top movers analysis in the middle of the day on 2025-05-28: top gainers and losers in today's session.
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
Crude Oil Gains 2%; Macy's Lowers Earnings Forecast
Via Benzinga
InflaRx Ends Lead Asset Development After Failed Study For Rare And Painful Skin Disease
InflaRx ends its Phase 3 trial of vilobelimab in pyoderma gangrenosum and shifts focus to INF904 amid efforts to extend its cash runway. 
Via Benzinga
These stocks are gapping in today's session
The market is buzzing with gapping stocks on Wednesday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
US Stocks Gain; Abercrombie & Fitch Posts Upbeat Earnings
 
Via Benzinga
Get insights into the top gainers and losers of Wednesday's pre-market session.
Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
Why Box Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
This Centessa Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday
 
Via Benzinga
Carnival To Rally Over 50%? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
Infinitum: Pioneering Quantum-Proof Blockchain Solutions to Transform Finance
Via ACCESS Newswire
Earnings Scheduled For March 20, 2025
 
Via Benzinga
Friday's session: top gainers and losers
Here are the top movers in Friday's session, showcasing the stocks with significant price changes. 
Via Chartmill
What's going on in today's session
Here are the top movers in Friday's session, showcasing the stocks with significant price changes. 
Via Chartmill
Friday's session: gap up and gap down stocks
The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
Top movers in Friday's pre-market session
Before the US market kicks off on Friday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
Get insights into the top gainers and losers of Thursday's after-hours session.
The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
IFRX Stock Earnings: InflaRx Misses EPS, Misses Revenue for Q2 2024
IFRX stock results show that InflaRx missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
IFRX Stock Earnings: InflaRx Beats EPS, Misses Revenue for Q1 2024
IFRX stock results show that InflaRx beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
IFRX Stock Earnings: InflaRx Misses EPS, Misses Revenue for Q4 2023
IFRX stock results show that InflaRx missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Earnings Scheduled For March 21, 2024
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.